Funding Announcements

"We are thrilled to welcome Silverstripe to the Shackle story. It has been great to build a really strong relationship with the team, and their experience and track record in the finance and tech sector will supercharge our mission to revolutionise the hotel industry."

"If we are going to deliver the energy transition required in time to meet global climate goals, we need to completely rethink worldwide energy infrastructure – transforming what we have, but also building considerably more, and doing so at an unprecedented pace. The best way to do that is to work smarter, not harder – as highlighted by the UK Electricity Networks Commissioner, automated infrastructure planning processes, such as those that we provide, have a big part to play. But the impact of technology needn’t be limited to the planning stage – we’re excited to bring its transformative power to developers throughout the development process as we continue to grow with this new funding."

"We invest in companies with the potential to become leaders in their field, and that is why we’re proud to back the incredible team at Navenio on their latest fundraise. Navenio is revolutionising the way we create more efficient healthcare workplaces, through its proven technology powered platform for indoor mapping, and we are excited to continue supporting the team on the next stage of the company’s journey as they look to deliver its offering to a wider range of use cases and across new geographies."

"Technology that operates autonomously, provides real-time insights, possesses intuitive interfaces, and seamlessly integrates can lead to a revolutionary transformation in the day-to-day efficiency, productivity and precision of warehouse operations"

"Our vision is a future where cell and gene therapies are safer, more efficient, and affordable for patients. Operating at the intersection of biology, bioinformatics and data science, our INDUCE-seq platform offers an unbiased, end-to-end solution that expedites the measurement and assessment of off-target gene editing during therapeutic development. This provides essential information required to progress therapeutic programs that leverage gene editing and mitigate potential risks that can result in later-stage clinical failures. By developing a deployable PaaS offering, we have the opportunity to provide the cell and gene therapy community with this much-needed solution and achieve rapid market growth."